Literature DB >> 25239481

Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium.

Adriaan Blommaert1, Joke Bilcke2, Yannick Vandendijck3, Germaine Hanquet4, Niel Hens5, Philippe Beutels6.   

Abstract

Risk groups with increased vulnerability for influenza complications such as pregnant women, persons with underlying illnesses as well as persons who come into contact with them, such as health care workers, are currently given priority (along with other classic target groups) to receive seasonal influenza vaccination in Belgium. We aimed to evaluate this policy from a health care payer perspective by cost-effectiveness analysis in the three specific target groups above, while accounting for effects beyond the target group. Increasing the coverage of influenza vaccination is likely to be cost-effective for pregnant women (median €6589 per quality-adjusted life-year (QALY) gained [€4073-€10,249]) and health care workers (median €24,096/QALY gained [€16,442-€36,342]), if this can be achieved without incurring additional administration costs. Assuming an additional physician's consult is charged to administer each additional vaccine dose, the cost-effectiveness of vaccinating pregnant women depends strongly on the extent of its impact on the neonate's health. For health care workers, the assumed number of preventable secondary infections has a strong influence on the cost-effectiveness. Vaccinating people with underlying illnesses is likely highly cost-effective above 50 years of age and borderline cost-effective for younger persons, depending on relative life expectancy and vaccine efficacy in this risk group compared to the general population. The case-fatality ratios of the target group, of the secondary affected groups and vaccine efficacy are key sources of uncertainty.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost-utility; Elderly; Flu; Immunocompromised; Pregnancy; Risk groups; Vaccination

Mesh:

Substances:

Year:  2014        PMID: 25239481     DOI: 10.1016/j.vaccine.2014.08.085

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions.

Authors:  Yueyuan Zhao; Xuefeng Zhang; Fengcai Zhu; Hui Jin; Bei Wang
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa.

Authors:  Matthew Biggerstaff; Cheryl Cohen; Carrie Reed; Stefano Tempia; Meredith L McMorrow; Sibongile Walaza; Jocelyn Moyes; Florette K Treurnicht; Adam L Cohen; Paul Hutchinson; Charles Stoecker; Joni Steinberg
Journal:  Vaccine       Date:  2019-09-28       Impact factor: 3.641

3.  Variation in loss of immunity shapes influenza epidemics and the impact of vaccination.

Authors:  Rutger G Woolthuis; Jacco Wallinga; Michiel van Boven
Journal:  BMC Infect Dis       Date:  2017-09-19       Impact factor: 3.090

4.  Economic evaluation of seasonal influenza vaccination in elderly and health workers: A systematic review and meta-analysis.

Authors:  Piyameth Dilokthornsakul; Le My Lan; Ammarin Thakkinstian; Raymond Hutubessy; Philipp Lambach; Nathorn Chaiyakunapruk
Journal:  EClinicalMedicine       Date:  2022-04-21

Review 5.  Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.

Authors:  Pieter T de Boer; Geert W J Frederix; Talitha L Feenstra; Pepijn Vemer
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

6.  Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50-64 Years, and At-Risk Adults Aged 19-64 Years.

Authors:  Min Joo Choi; Gyeongseon Shin; Daewon Kang; Jae-Ok Lim; Yun-Kyung Kim; Won Suk Choi; Jae-Won Yun; Ji Yun Noh; Joon Young Song; Woo Joo Kim; Sang-Eun Choi; Hee Jin Cheong
Journal:  Vaccines (Basel)       Date:  2022-03-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.